Share-based Payment Arrangement, Expense of AYTU BIOPHARMA, INC from 31 Mar 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AYTU BIOPHARMA, INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 31 Dec 2025.
  • AYTU BIOPHARMA, INC Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $283,000, a 87% increase year-over-year.
  • AYTU BIOPHARMA, INC Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $649,000, a 56% decline year-over-year.
  • AYTU BIOPHARMA, INC annual Share-based Payment Arrangement, Expense for 2025 was $576,000, a 80% decline from 2024.
  • AYTU BIOPHARMA, INC annual Share-based Payment Arrangement, Expense for 2024 was $2,913,000, a 52% decline from 2023.
  • AYTU BIOPHARMA, INC annual Share-based Payment Arrangement, Expense for 2023 was $6,046,000, a 15% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AYTU BIOPHARMA, INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $649,000 $283,000 +$132,000 +87% 01 Oct 2025 31 Dec 2025 10-Q 03 Feb 2026 2026 Q2
Q3 2025 $517,000 $114,000 -$59,000 -34% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q1
Q2 2025 $576,000 $113,000 -$239,000 -68% 01 Apr 2025 30 Jun 2025 10-K 23 Sep 2025 2025 FY
Q1 2025 $815,000 $139,000 -$672,000 -83% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q3
Q4 2024 $1,487,000 $151,000 -$669,000 -82% 01 Oct 2024 31 Dec 2024 10-Q 03 Feb 2026 2026 Q2
Q3 2024 $2,156,000 $173,000 -$757,000 -81% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q1
Q2 2024 $2,913,000 $352,000 -$548,000 -61% 01 Apr 2024 30 Jun 2024 10-K 23 Sep 2025 2025 FY
Q1 2024 $3,461,000 $811,000 -$91,000 -10% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q3
Q4 2023 $3,552,000 $820,000 -$2,247,000 -73% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2025 Q2
Q3 2023 $5,799,000 $930,000 -$247,000 -21% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2025 Q1
Q2 2023 $6,046,000 $900,000 -$330,000 -27% 01 Apr 2023 30 Jun 2023 10-K 26 Sep 2024 2024 FY
Q1 2023 $6,376,000 $902,000 -$368,000 -29% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q3
Q4 2022 $6,744,000 $3,067,000 +$1,838,000 +150% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q2
Q3 2022 $4,906,000 $1,177,000 -$342,000 -23% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q1
Q2 2022 $5,248,000 $1,230,000 +$141,000 +13% 01 Apr 2022 30 Jun 2022 10-K 12 Oct 2023 2023 FY
Q1 2022 $5,107,000 $1,270,000 -$252,000 -17% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q3
Q4 2021 $5,359,000 $1,229,000 +$721,000 +142% 01 Oct 2021 31 Dec 2021 10-Q 21 Feb 2023 2023 Q2
Q3 2021 $4,638,000 $1,519,000 +$1,064,000 +234% 01 Jul 2021 30 Sep 2021 10-Q/A 21 Feb 2023 2023 Q1
Q2 2021 $3,574,000 $1,089,000 +$601,000 +123% 01 Apr 2021 30 Jun 2021 10-K 27 Sep 2022 2022 FY
Q1 2021 $2,973,000 $1,522,000 +$1,258,000 +477% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q3
Q4 2020 $1,715,000 $508,000 +$346,000 +214% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2022 Q2
Q3 2020 $1,369,000 $455,000 +$290,000 +176% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q1
Q2 2020 $1,079,000 $488,000 +$189,000 +63% 01 Apr 2020 30 Jun 2020 10-K 28 Sep 2021 2021 FY
Q1 2020 $890,000 $264,000 -$113,000 -30% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q3
Q4 2019 $1,003,000 $162,000 -$32,000 -16% 01 Oct 2019 31 Dec 2019 10-Q 14 Feb 2020 2020 Q2
Q3 2019 $1,035,000 $165,000 +$13,000 +8.6% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2021 Q1
Q2 2019 $1,022,000 $299,000 +$149,000 +99% 01 Apr 2019 30 Jun 2019 10-K 06 Oct 2020 2020 FY
Q1 2019 $873,000 $377,000 +$310,000 +463% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q3
Q4 2018 $563,000 $194,000 +$81,000 +72% 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2020 2020 Q2
Q3 2018 $482,000 $152,000 -$115,000 -43% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2020 Q1
Q2 2018 $597,000 $150,000 -$179,000 -54% 01 Apr 2018 30 Jun 2018 10-K 26 Sep 2019 2020 FY
Q1 2018 $776,000 $67,000 -$1,249,000 -95% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q3
Q4 2017 $2,025,000 $113,000 -$350,000 -76% 01 Oct 2017 31 Dec 2017 10-Q 14 May 2019 2019 Q2
Q3 2017 $2,375,000 $267,000 -$852,000 -76% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2019 Q1
Q2 2017 $3,227,000 $329,000 01 Apr 2017 30 Jun 2017 10-K 06 Sep 2018 2018 FY
Q1 2017 $1,316,000 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q3
Q4 2016 $463,000 +$280,000 +153% 01 Oct 2016 31 Dec 2016 10-Q 08 Feb 2018 2018 Q2
Q3 2016 $1,119,000 +$1,051,000 +1546% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2018 Q1
Q4 2015 $791,000 $183,000 -$93,000 -34% 01 Oct 2015 31 Dec 2015 10-Q 11 Feb 2016 2016 Q2
Q3 2015 $884,000 $68,000 -$134,000 -66% 01 Jul 2015 30 Sep 2015 10-Q 06 Nov 2015 2015 Q1
Q2 2015 $1,018,000 $268,000 01 Apr 2015 30 Jun 2015 10-K 28 Sep 2015 2015 FY
Q1 2015 $272,000 +$188,000 +224% 01 Jan 2015 31 Mar 2015 10-Q 19 May 2015 2015 Q3
Q4 2014 $276,000 01 Oct 2014 31 Dec 2014 10-Q 11 Feb 2016 2016 Q2
Q3 2014 $202,000 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q1
Q1 2014 $84,000 01 Jan 2014 31 Mar 2014 10-Q 19 May 2015 2015 Q3

AYTU BIOPHARMA, INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $576,000 -$2,337,000 -80% 01 Jul 2024 30 Jun 2025 10-K 23 Sep 2025 2025 FY
2024 $2,913,000 -$3,133,000 -52% 01 Jul 2023 30 Jun 2024 10-K 23 Sep 2025 2025 FY
2023 $6,046,000 +$798,000 +15% 01 Jul 2022 30 Jun 2023 10-K 26 Sep 2024 2024 FY
2022 $5,248,000 +$1,674,000 +47% 01 Jul 2021 30 Jun 2022 10-K 12 Oct 2023 2023 FY
2021 $3,574,000 +$2,495,000 +231% 01 Jul 2020 30 Jun 2021 10-K 27 Sep 2022 2022 FY
2020 $1,079,000 +$57,000 +5.6% 01 Jul 2019 30 Jun 2020 10-K 28 Sep 2021 2021 FY
2019 $1,022,000 +$425,000 +71% 01 Jul 2018 30 Jun 2019 10-K 06 Oct 2020 2020 FY
2018 $597,000 -$2,630,000 -82% 01 Jul 2017 30 Jun 2018 10-K 26 Sep 2019 2020 FY
2017 $3,227,000 +$2,324,000 +257% 01 Jul 2016 30 Jun 2017 10-K 06 Sep 2018 2018 FY
2016 $903,000 -$115,000 -11% 01 Jul 2015 30 Jun 2016 10-K 31 Aug 2017 2017 FY
2015 $1,018,000 +$518,000 +104% 01 Jul 2014 30 Jun 2015 10-K 28 Sep 2015 2015 FY
2014 $500,000 01 Jul 2013 30 Jun 2014 10-K 28 Sep 2015 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.